

ATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing: 02 June 2000 (02.06.00)	
International application No.: PCT/DK99/00425	Applicant's or agent's file reference:
International filing date: 29 July 1999 (29.07.99)	Priority date: 20 November 1998 (20.11.98)
Applicant: ANDREASEN, Hans, Berg et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International preliminary Examining Authority on:

28 February 2000 (28.02.00)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer: J. Zahra Telephone No.: (41-22) 338.83.38
---	---

ATTENT COOPERATION TRE

PCT

From the INTERNATIONAL BUREAU

To:

SIMONSEN, Christian, Rosendal
 Internationalt Patent-Bureau
 Høje Taastrup Boulevard 23
 DK-2630 Taastrup
 DANEMARK

Date of mailing (day/month/year)
 25 September 2000 (25.09.00)

Applicant's or agent's file reference

IMPORTANT NOTIFICATION

International application No.
 PCT/DK99/00425

International filing date (day/month/year)
 29 July 1999 (29.07.99)

1. The following indications appeared on record concerning:

the applicant the inventor the agent the common representative

Name and Address

NEBO A/S
 Frederiksborgvej 27
 DK-4000 Roskilde
 Denmark

State of Nationality	State of Residence
DK	DK
Telephone No.	
Facsimile No.	
Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

the person the name the address the nationality the residence

Name and Address

PHARMACOSMOS HOLDING A/S
 Frederiksborgvej 27
 DK-4000 Roskilde
 Denmark

State of Nationality	State of Residence
DK	DK
Telephone No.	
Facsimile No.	
Teleprinter No.	

3. Further observations, if necessary:

This form completes form IB/306 issued on 24 Nov 2000: the name of NEBO INDUSTRIES A/S had been changed into NEBO A/S, before the assignment to the new applicant PHARMACOSMOS HOLDING A/S.

4. A copy of this notification has been sent to:

the receiving Office the designated Offices concerned
 the International Searching Authority the elected Offices concerned
 the International Preliminary Examining Authority other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Ingrid Aulich Telephone No.: (41-22) 338.83.38
---	---

09509681
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 31/715, 31/295, 47/48, C08B 37/00</p>		<p>(11) International Publication Number: WO 00/30657</p>
		<p>(43) International Publication Date: 2 June 2000 (02.06.00)</p>
<p>(21) International Application Number: PCT/DK99/00425</p> <p>(22) International Filing Date: 29 July 1999 (29.07.99)</p> <p>(30) Priority Data: PA 1998 01526 20 November 1998 (20.11.98) DK</p> <p>(71) Applicant (<i>for all designated States except US</i>): PHARMACOSMOS HOLDING A/S [DK/DK]; Frederiksborgvej 27, DK-4000 Roskilde (DK).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): ANDREASEN, Hans, Berg [DK/DK]; Vænget 2, DK-4130 Viby Skaelland (DK). CHRISTENSEN, Lars [DK/DK]; Frederiksborgvej 27, DK-4000 Roskilde (DK).</p> <p>(74) Agents: SIMONSEN, Christian, Rosendal et al.; International Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).</p>		
<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>With amended claims and statement.</i></p>		
<p>(54) Title: A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND</p> <p>(57) Abstract</p> <p>In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A PROCESS FOR PRODUCING AN IRON-DEXTRAN COMPOUND

5

BACKGROUND OF THE INVENTION AND PRIOR ART

10 Iron-deficiency anemia has been described as one of the most common - possibly the most common - pathological conditions among humans when viewed on a global basis. Also in modern farm-breeding of pigs and other domestic animals iron-deficiency anemia is a problem 15 unless suitable prophylactic measures are taken.

Although iron-deficiency anemia can often be prevented or cured by oral administration of iron-containing preparations, it is in many cases preferred to use parenterally administrable iron preparations to avoid 20 variations in bioavailability of oral administrations and to ensure effective administration.

Therefore, iron-containing preparations for parenteral use, i.e. subcutaneous, intramuscular or intravenous administration, have for many years been at 25 the disposal of the veterinary or human medical practitioner.

Various iron-containing substances have been used or suggested as components in parenterally injectable preparations against iron-deficiency anemia, such as 30 saccharated ferric oxide. However, the most common preparations accepted today are such which comprise a combined product of ferric oxyhydroxide (or ferric hydroxide) in association with dextran since such preparations are less toxic than for instance the 35 ferric saccharates. Dextran is a polymeric carbohydrate

produced by the microorganisms *Leuconostoc mesenteroides*.

An iron-containing preparation for parenteral injection should obviously satisfy several requirements 5 including ready availability of the iron for haemoglobin synthesis, absence of local or general side-effects and stability on storage enabling a satisfactory shelf-life at ambient temperature.

Iron-dextran preparations for the treatment of 10 anemia have been marketed for decades, and many variations in the manufacturing process and in the selection of starting materials have been suggested with a view to improving the stability of such preparations and to decrease the amount of side effects obtained at 15 their administration.

As examples of patents dealing with these problems the following may be cited:

US 2,885,393 (1959) describes a basical process of producing an iron-dextran complex in which the average 20 molecular weight of the dextran is 30,000 to 80,000 Daltons (Da) or lower. The suitability of these complexes for human therapy does not appear from this patent specification.

US Re. 24,642 (1959) comprises a detailed explanation of the requirements to an iron solution intended 25 for intramuscular injection, incorporated herein by reference. The patent deals with a substantially nonionic complex of ferric hydroxide with a dextran having an average intrinsic viscosity at 25°C of about 0.025 30 to about 0.25, as well as a process for preparing such a complex by contacting a dextran as described with ferric hydroxide formed *in situ* by reaction between a ferric salt and an alkali base. No information as to the desired molecular weight of the dextran is given,

and no chemical modification of the dextran, apart from a partial depolymerisation, is suggested.

US 3,093,545 (1963). This patent discloses some details such as temperatures and pH-values in an 5 improved method of preparing a product apparently very similar to the one prepared in the last mentioned above patent.

GB 1,200,902 (1970) teaches that in contrast to preparing the ferric hydroxide *in situ* it is advantageous to preform the ferric hydroxide under controlled conditions since such ferric hydroxide will readily form complexes with dextrans. It is stated that not only partially depolymerised dextran having a weight average molecular weight in the range of for example 15 500-50,000 Da, preferably in the range 1,000- 10,000 Da, but also modified forms or derivatives of dextran such as hydrogenated dextrans or oxidised dextrans or alkali treated dextrans come into consideration as theoretical possibilities. However, the only dextrans 20 specifically mentioned are oxidized dextrans having an average molecular weight of 3,000 and 5,000 Da, resp. The ferric hydroxide is preprepared before contact with the dextran. This means that the resulting product consists of ferric oxyhydroxide on which the dextran 25 forms a coating in contrast to the more homogeneous products formed by precipitatig the ferric hydroxide *in situ*, that means in the presence of the dextran.

DK 117,730 (1970) deals with a process in which hydrogenated dextran having a molecular weight between 30 2,000 and 10,000 Da is reacted with ferric hydroxide in aqueous medium. The average molecular weight of the dextran used in the embodiment examples is not indicated. However, the intrinsic viscosity is stated as approximately 0,05 which could correspond to an 35 average molecular weight of approximately 5,000 Da.

DK 122,398 (1972) also discloses the use of hydrogenated dextran for preparing complex compounds with ferric hydroxide, and it is explained that a substantially lower toxicity is obtained than when non-
5 hydrogenated dextran is used. The subject of the patent is a process in which moist ferric hydroxide is mixed with dry hydrogenated dextran, and after optional addition of citric acid or citrate the mixture is heated and purified.

10 US 3,697,502 (1972) discloses a process for producing an iron-dextran preparation in which citric acid is added to the dextran and a simultaneous addition of alkali metal hydroxide solution and ferric chloride solution is made. The average molecular weight of the
15 dextran is between 3,000 and 20,000 Da. The dextran used in the embodiment examples has a molecular weight of 7,000 and 10,000 Da, resp.

DK 129,353 (1974) is directed on an analogy process for producing a ferric hydroxide-dextran derivative at an average molecular weight of the dextran of at the most 50,000 Da, and the terminal groups of the polymer chains thereof have been modified to convert the terminal reducing anhydroglucose unit into a corresponding carboxylic acid group. Although the
25 limits indicated for molecular weight of the dextran are very broad, viz. from 500 to 50,000 Da, preferably from 1,000 to 10,000 Da, the only exemplified dextran has an average molecular weight of 5,000 Da.

DK 129,942 (1974) has similarity to the above
30 last-mentioned DK patent and deals with the manufacture of ferric hydroxide complexes with dextran hepton acid or dextrine hepton acid. The hepton acids are prepared by hydrolyzing the corresponding cyanhydrids.

US 4,827,945 (1989) and 5,102,652 (1992) both deal
35 with superparamagnetic metal oxides such as iron oxides

coated with or associated with polymeric materials such as dextran. The polymer is contacted with a mixture of the metal oxides in two different oxidation stages to produce a superparamagnetic combined product which is 5 afterwards oxidized to transform all the metal oxide into the highest of said oxidation steps. The product is especially useful as contrast agent in magnetic resonance imaging in medical diagnosis. However, it is also mentioned that it can be used for treatment of 10 iron-deficiency anemia. The molecular weight of the polymers, including carbohydrates such as dextran, are preferably from 5,000 to 250,000 Da.

In spite of the several attempts to improve iron-dextran preparations for treatment of anemia, as 15 reflected in the above patents, the preparations prepared according to the state of the art still have some drawbacks.

This is a result of the fact that in some patients the preparations may cause delayed hypersensitivity, or 20 severe anaphylactic side effects, resulting e.g. in dyspnea, hypotension, shock and death. Also other toxic reactions might be observed.

Besides, several of the prior art preparations are not able to meet current requirements as to stability. 25 Lacking stability may manifest itself as gelatination of the liquid or precipitation of iron hydroxide or oxyhydroxide.

Moreover, the promoting action of the commercially available iron-dextran preparations on the haemoglobin 30 synthesis in the patients receiving said preparations presents itself rather late after administration, and reestablishment of desired haemoglobin levels takes place more slowly than often desired.

COPENDING ART

Copending non-published Danish patent application 420/98 (incorporated herein by reference) discloses an 5 invention by means of which certain of the above mentioned drawbacks are overcome. Said invention is based on the recognition that many of the specified drawbacks are associated with the presence of insufficiently hydrolyzed, relatively high-molecular 10 weight dextran in the dextran used as starting material as well as with the presence of low-molecular weight saccharides therein.

This recognition is utilized to produce, i.a. by means of membrane technique, an iron-dextran compound 15 which is characterized in that it comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Da, preferably approximately 1,000 Da, a number average molecular weight (Mn) of 400 to 1,400 Da and wherein 90% by 20 weight of the dextran has molecular weights less than 2,700 Da and the Mw of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Da, in stable association with ferric oxyhydroxide.

25

SUMMARY OF THE INVENTION

Although the product of the above cited Danish Patent Application 420/98 presents a substantial 30 improvement as to decreased toxic reactions and reduced tendency of causing hypersensitivity or anaphylactic side effects and also involves improvements as to stability, there still is a need for a means of controlling the average molecular weight of the final 35 iron-dextran compound, and thus the availability of the

iron for haemoglobin synthesis in the human or animal organism.

If an iron-dextran compound having an iron content of e.g. 15-45% b.w. is prepared using a dextran having a weight average molecular weight of approximately 1,000 Da, in which dextran substantially all reducing aldehyde groups have been hydrogenated to alcohol groups, the apparent peak molecular weight (Mp) will typically be approximately 140,000 Da.

10 It is desired to be able to produce iron-dextran compounds of lower molecular weight and improved stability, especially to obtain compounds in which the iron is readily available for haemoglobin synthesis in the human or animal organisms.

15 The present invention is based on the recognition that a stable iron-dextran of relatively low molecular weight may be obtained if the reducing aldehyde groups of the hydrolyzed dextran, before the reaction with the iron component, are only partially hydrogenated into 20 alcohol groups whereas substantially all the remaining aldehyde groups are oxidized into carboxylic groups. The molecular weight of the iron-dextran formed when the dextran has received such a pretreatment is substantially lower than the molecular weight of an 25 iron-dextran produced using a similar hydrolyzed dextran having been pretreated only by a, possibly complete, hydrogenation. By adjusting the ratio of the amount of reducing groups hydrogenated to the amount of reducing groups oxidized, it is possible to influence 30 the average molecular weight of the resulting iron-dextran compound. However, if the proportion of oxidized groups in the dextran is too high the iron-dextran will have insufficient stability. It has turned out that to obtain a stable product, the amount of

reducing groups in the dextran before oxidation must not exceed a value corresponding to 15% by weight.

Thus, the present invention deals with a process for producing a stable iron-dextran compound having a 5 relatively low molecular weight and a narrow molecular weight distribution, in which process the molecular weight of a dextran is reduced by hydrolysis, and functional aldehyde terminal groups thereof are converted into alcohol groups by hydrogenation, the 10 hydrogenated dextran as an aqueous solution is combined with at least one water-soluble ferric salt, base is added to the resulting solution to form ferric hydroxide, and the resulting mixture is heated to transform the ferric hydroxide into ferric oxyhydroxide 15 as an association compound with the dextran, which process is characterized in that the hydrogenation is only partial, leaving, however, at the most 15% by weight reducing sugar, calculated on the total amount of carbon hydrates, and said dextran before being 20 combined with the ferric salt, and after being subjected to hydrogenation is subjected to an oxidation, said hydrogenation and oxidation being performed to obtain dextran having substantially all aldehyde 25 groups converted into alcohol and carboxylic groups.

25 Thus, the hydrogenation is performed before the oxidation as a partial hydrogenation leaving a portion of the aldehyde groups of the dextran unreacted, and the oxidation is performed subsequently to obtain a substantially complete conversion of said portion of 30 aldehyde groups into carboxylic acid groups.

It is believed that by this sequence of the hydrogenation and oxidation an advantageous distribution of the resulting alcohol and carboxylic acid group is obtained, since by performing the hydro- 35 genation as an initial operation, the alcohol forming

hydrogenation primarily takes place in those aldehyde groups attached to the relatively low molecular weight dextran molecules, whereas the aldehyde groups on the higher molecular weight dextrans are primarily reacted 5 in the oxidation step which means that the carboxylic acid groups formed by the oxidation will to a large extent be introduced in the dextran of higher molecular weight.

This distribution of the alcohol groups and the 10 carboxylic acid groups on the lower molecular weight fraction and the higher molecular weight fraction, resp., is an advantage because it is to expect that the stability of the resulting product will be better than if the alcohol and carboxylic acid groups were distributed 15 at random, and especially better than if the carboxylic acid groups were primarily present on the lower molecular weight portion of the dextran.

However, this invention is not limited to any specific theory concerning the reason for the 20 satisfactory stability of the product produced by said preferred embodiment.

In relatively low molecular weight dextrans as those primarily coming into consideration according to the present invention the influence of the terminal 25 groups (aldehyde groups hydrogenated into alcohol groups or oxidated into carboxylic acid groups) on the polymer chains is substantially more pronounced than in dextrans of higher molecular weight, since the fraction (on weight basis) of functional terminal groups is 30 higher. Therefore, it is important that the carboxylic acid groups, which otherwise could cause instability, are present on the relative high molecular weight fraction of the dextran molecules.

It is preferred to perform the hydrogenation by 35 means of sodium borohydride in aqueous solution.

The oxidation is preferably performed by means of a hypochlorite, preferably sodium hypochlorite, in basic, aqueous solution.

It is important that an oxydant is used having an 5 oxydative capacity suitable for transforming the aldehyde groups into carboxylic acid groups without attacking other sites of the dextran molecules. By tests based on NMR-analysis of the resulting dextrans it has turned out that sodium hypochlorite is a 10 suitable oxydant in this respect, since it seems that all oxygen atoms introduced by the oxidation are present in the carboxylic acid groups.

The process of the present invention is in principle not limited to the use of dextrans having 15 specific molecular weights and molecular weight distribution, however it is prefered to use a dextran having before the formation of the iron-dextran a molecular weight lower than 7,500 Da. To obtain a product which by overall considerations is regarded as 20 most suitable for treatment of iron-deficiency anemia, an embodiment of the process is preferred which is characterized in that after the hydrolysis but before being combined with the water soluble ferric salt, the dextran is purified by one or more membrane processes 25 using a membrane having a cut-off value suitable for holding back dextran of molecular weight above 2,700 Da, possibly followed by further hydrolysis, and followed by one or more membrane processes using membranes with a cut-off between 340 and 800 Da 30 removing the smaller molecules.

A more specifically preferred embodiment comprises the following terminal steps of the process:

preparing an aqueous solution comprising the purified hydrogenated and oxydized dextran and at least 35 one water-soluble ferric salt;

adjusting the pH of said aqueous solution to a value above 10 by addition of a base;

heating the mixture to a temperature above 100°C until it turns to a black or dark brown colloidal solution which can be filtered through a 0.45 μm filter; and

further neutralization, purification and stabilization using filtration, heating and membrane processes and addition of one or more stabilizers, and 10 optionally drying the solution to obtain the desired iron-dextran compound as a stable powder. Injection liquids may be produced by redissolving this powder, adjustment of pH, sterilizing by filtration and filling into ampoules or vials. Sterilization may also be 15 accomplished by autoclaving the filled ampoules or vials.

Alternatively the drying operation is omitted, and an injection liquid is produced from the purified solution without intermediate drying thereof.

20 As explained above, a feature of the invention is the adjustment of the ratio of hydrogenated dextran aldehyde groups to the oxidized aldehyde dextran groups, as well as the total percentage of such groups.

25 It is essential that substantially all reducing groups in the hydrolysed dextran used as starting material are converted by the hydrogenation or the oxidation. This is because any remaining reducing groups react with the ferric compounds when contacted 30 therewith to form ferro compounds which by parenterally administration are more toxic than ferric compounds.

Thus, a further preferred embodiment of the process of the invention is characterized in that the oxidation of the hydrolyzed and hydrogenated dextran is 35 performed to decrease the content of reducing sugar to

not above 4% b.w. The amount of reducing sugar in the hydrolysed dextran before hydrogenation is in no way critical and will typically be in the range 20-50% b.w.

The invention also comprises an iron-dextran compound produced according to the above defined process which compound is characterized in that the apparent peak molecular weight (M_p) thereof is 50,000-150,000 Da, preferably 70,000-130,000 Da, more preferably 80,000-120,000 Da, and its iron content is 15-45% b.w. When an aqueous preparation of such an iron-dextran compound is injected intra-muscularly to a patient suffering from iron-deficiency anemia, a positive influence on the haemoglobin production can be observed earlier than when a corresponding amount of 15 iron is injected in a preparation based on the commercial iron-dextran compounds having an apparent peak molecular weight of not below 150,000 Da.

In the present specification and in the attached claims the indications of molecular weights refer to 20 such weights determined by gel-permeation chromatography.

Stability was evaluated as the absence of visible detrimental changes, such as gel formation or precipitation, of the product after heating to 70°C or 25 more for 10 min.

The invention further comprises a pharmaceutical composition for prophylaxis or treatment of iron-deficiency by parenteral administration, which composition is characterized in that it comprises a 30 compound as defined above.

Such pharmaceutical composition preferably further comprises a salt of an organic hydroxy acid, preferably selected from citrates and gluconates as stabilizer.

Finally, the invention comprises the use of an 35 iron-dextran compound as defined above for the

preparation of a parenterally administerable therapeutic composition for prophylaxis or treatment of iron-deficiency by parenteral administration.

The invention is further illustrated by means of 5 the following non-limiting examples.

EXAMPLE 1

10 (i) **Hydrolysis, hydrogenation and oxidation of dextran**

2,522 kg hydrolyzed dextran collected as permeate from a membrane having a cut-off value < 5,000 Da, is hydrolyzed at pH 1.5 at a temperature of 95°C.

15 The hydrolysis is monitored chromatographically using gel permeation chromatography (GPC), and is terminated by cooling when the molecular weight of the material being hydrolyzed is estimated to have achieved the desired value, i.e. a weight average molecular weight of 700-1,400 Da.

20 By the hydrolysis low molecular weight dextran is produced but also glucose is formed. After cooling and neutralization the amount of glucose and very low molecular weight oligomers is reduced by membrane processes having a cut-off value of 340-800 Da. After this 25 process, the content of dextran is determined by optical rotation ($\alpha_D^{20} \sim 200$) to be 1,976 kg, and the amount of reducing sugar is determined by use of Somogyi's reagent to be 32.0% b.w.

30 The reducing capability is first decreased by treatment with sodium borohydride. For 939 kg dextran 18,4 kg sodium borohydride is added at basic pH. By this partial hydrogenation it is expected that among the aldehyde groups which are hydrogenated, those dextran with relatively low molecular weight 35 preponderate.

After the sodium borohydride treatment, the reducing capability is determined to 6.53% b.w.

Hereafter the solution is neutralized to pH < 7.0, and subsequently de-ionized. The average molecular weights and the molecular weight distribution is determined chromatographically.

The chromatography also reveals that 90% by weight of the dextran has molecular weights less than 2,700 Da and that the weight average molecular weight (Mw) of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Da.

Mw is found to be 1,200 and the number average molecular weight (Mn) is 800 Da.

Thereafter oxidation is performed using sodium hypochlorite at pH 9.5 and at 50°C. 1075 l of an aqueous 15% w/v NaOCl solution is added.

After the termination of the oxidation, reducing sugar is determined as 0.9% b.w.

After the oxidation diafiltration is performed against pure water to obtain a specific conductivity of 3 mS/cm. The amount of dextran was at this stage 635 kg. NMR-analysis showed that all double-bonded oxygen atoms were present as carboxylic acid groups.

25 (ii) **Synthesis of iron-dextran**

300 kg dextran, produced as above, is as an 15% solution mixed with 300 kg FeCl₃, 6H₂O.

To the agitated mixture, 250 kg Na₂CO₃ as a saturated aqueous solution is added to obtain pH 3.5, and, thereafter, the pH is raised to 11.5 using 50 litres concentrated aqueous NaOH (27% w/v).

The mixture thus obtained is heated above 100°C until it turns to a black or dark brown colloidal solution that can be filtered through a 0.45 µm filter. 35 The solution is cooled, neutralized to pH 5.00 using

concentrated hydrochloric acid, and filtered. The solution is purified using membrane processes until the chloride content in the solution is less than 0.68% calculated on basis of a solution containing 5% w/v 5 iron.

If the chloride content of the solution is less than desired to obtain an isotonic solution, sodium chloride is added and pH is finally adjusted to 5.6 and the solution is filtered through a 0.45 μm (or alternatively a 0.2 μm) membrane filter.

The solution is spray dried and the iron-dextran powder is ready for marketing or for further processing.

As alternative to spray drying, the solution can 15 be used for direct production of injection liquids having an iron content of e.g. 5%, as described above.

When using the iron-dextran powder for producing injection or infusion liquids the powder is re-disolved in an aqueous medium, the pH is checked, and, if 20 necessary, adjusted, and the solution is filled into ampoules or vials after being sterilized by filtration. Alternatively, the sterilization can take place by autoclaving after filling into ampoules or vials.

25 EXAMPLE 2

(i) Hydrolysis, hydrogenation and oxidation of dextran

This portion of the synthesis is performed as described under (i) in Example 1 above.

30

(ii) Synthesis of iron-dextran

240 kg of the above mentioned dextran as an 12% solution is mixed with 300 kg $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$.

To the agitated mixture is added 250 kg Na_2CO_3 as 35 a saturated aqueous solution to obtain a pH-value of

3.5, and thereafter the pH of the mixture is raised to pH 11.6 using 50 litres concentrated aqueous NaOH (27% w/v).

The mixture thus obtained is heated above 100°C 5 until it turns to a black or dark brown colloidal solution that can be filtered through a 0.45 μm filter. The solution is cooled, neutralized to pH of 5.3 using concentrated hydrochloric acid and filtered. The solution is purified using membrane processes until the 10 chloride content is less than 0.68% calculated on basis of a solution containing 5% w/v iron.

If the solution is at this stage heated to above 100°C for 2 hours the apparent peak molecular weight (Mp) is found to be 104898 Da after cooling. The 15 solution is stable.

The solution is spray dried and the iron-dextran powder is thus finished.

This powder is suitable for producing a liquid iron-dextran preparation containing approximately 5% 20 w/v iron.

In both examples, the yield of iron-dextran powder is above 95%, calculated on basis of the iron used in the process.

25 EXAMPLE 3

Further iron-dextran preparations were produced using the procedures similar to the one described in Example 1 and 2. The characteristics of the starting materials, the intermediates and the results are shown 30 in the below table.

Table

Synthesis No.	1	2	3	4	5
5 Mw of hydrolyzed dextran (Da)	6200	2566	1212	1212	922
10 Reducing sugars after reduction step	4.4% b.w.	14.4% b.w.	6.5% b.w.	6.5% b.w.	8.9% b.w.
15 Reducing sugars after oxidation step	1.2% b.w.	3.0% b.w.	0.9% b.w.	0.9% b.w.	1.8% b.w.
20 Used amount of reduced and oxidized dextran	240 kg	240 kg	300 kg	240 kg	240 kg
25 Used amount of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$	300 kg	300 kg	300 kg	300 kg	300 kg
Mp of iron-dextran (Da)	126,350	102,653	88,146	96,875	88,326
Stable	Yes	Yes	Yes	Yes	Yes*

*) : Stability test at 70°C for 10 min.

30 It is thus possible to produce stable low molecular weight iron-dextran preparations using dextrans hydrogenated and oxidized to various extents within the scope of the invention.

35 EXAMPLE 4 (Comparison Example)

604 kg of a dextran with a Mw of 1209 Da and a content of reducing sugars of 26.6% b.w. was, without previous hydrogenation, oxidized by treatment with 1780 40 l of a 15% (w/v) solution of NaOCl in water at pH 9.5,

temperature 50°C. After the oxidation the content of reducing sugars was determined to 0.54%.

Preliminary attempt to synthesize iron-dextran compounds using this oxidized dextran failed because 5 the mixture containing iron and dextran formed a gel even before all the Na₂CO₃ was added. Heating such a gelling solution does not lead to formation of a stable colloidal and filterable solution.

This Example shows that it is essential to 10 decrease the proportion of reducing groups in the dextran by hydrogenation before performing the oxidation.

EXAMPLE 5

15

An iron-dextran solution was prepared as in Example 2.

After the chloride removing membrane process, the pH was adjusted to 8.5 using 10.5 kg citric acid 20 dissolved in an aqueous sodium hydroxide solution. The solution was then heated to above 100°C for 2 hours. After cooling, the pH is adjusted to 5.6 using concentrated hydrochloric acid. The solution is adjusted to a concentration corresponding to 5.0 w/v% iron. The 25 apparent peak molecular weight is determined to 111,666 and the compound is stable.

By comparing this Example with the Example 2 it appears that the addition of citrate does not significantly alter the molecular weight of the iron-dextran 30 product.

P A T E N T C L A I M S

1. A process for producing an iron-dextran compound, in which the molecular weight of a dextran is reduced by hydrolysis, and functional aldehyde terminal 5 groups thereof converted into alcohol groups by hydrogenation; said dextran as an aqueous solution is combined with at least one water-soluble ferric salt; base is added to the resulting solution to form ferric hydroxide, and the resulting mixture is heated to 10 transform the ferric hydroxide into ferric oxyhydroxide as an association compound with the dextran, characterized in that the hydrogenation is only partial leaving, however, at the most 15% by weight reducing sugar, calculated on the total amount 15 of carbon hydrates, and said dextran before being combined with the ferric salt, and after being subjected to hydrogenation is subjected to an oxidation, said hydrogenation and oxidation being performed to obtain dextran having substantially all aldehyde groups 20 converted into alcohol and carboxylic groups.

2. A process according to claim 1, characterized in that the dextran before being combined with the at least one ferric salt has a weight mean molecular weight less than 7,000 Da.

25 3. A process according to claim 1, characterized in that after the hydrolysis, but before being combined with the water-soluble ferric salt, the dextran is purified by one or more membrane separations having a cut-off value suitable for holding back dextran molecules above 2,700 Da, possibly followed by 30 further hydrolysis, and one or more membrane separations having a cut-off value between 340 and 800 Da removing the smaller molecules.

4. A process according to any of claims 1-3, 35 characterized in that the dextran

molecules have a reducing sugar content not above 4% b.w. after the oxidation.

5. A process according to any of claims 1-4, characterized in that the hydrogenation is performed by means of sodium borohydride in aqueous solution.

6. A process according to any of claims 1-5, characterized in that the oxidation is performed by means of a hypochlorite, preferably sodium hypochlorite in basic aqueous solution.

7. A process according to any of the preceding claims, characterized in the following steps:

preparing an aqueous solution comprising the 15 hydrogenated and oxidized dextran and at least one water-soluble ferric salt;

adjusting the pH of said aqueous solution to a value above 10 by addition of a base;

heating the mixture to a temperature above 100°C 20 until it turns into a black or dark brown colloidal solution and is filterable through a 0.45 µm filter;

purification and stabilization of the solution using filtration, heating and membrane separations and addition of one or more stabilizers, and

25 optionally drying the solution to obtain the desired iron-dextran compound as a stable powder.

8. A process according to claim 7, characterized in that the stabilisation comprises addition of at least one salt of an organic hydroxy 30 acid, preferably selected from citrates and gluconates.

9. Iron-dextran compound produced according to claims 1-8, characterized in that its apparent peak molecular weight (Mp) is 50,000 -150,000 Da, preferably 70,000-130,000, more preferably 80,000- 35 120,000 Da and its iron content is 15-45% b.w.

10. A pharmaceutical composition for prophylaxis or treatment of iron-deficiency by parenteral administration comprising a compound according to claim 9.

11. A pharmaceutical composition according to claim 10, characterized in that it comprises a salt of an organic hydroxy acid, preferably selected from citrates and gluconates as stabilizer.

12. Use of an iron-dextran compound according to claim 9 for preparation of a parenterally administrable therapeutic composition for prophylaxis or treatment of iron-deficiency by parenteral administration.

AMENDED CLAIMS

[received by the International Bureau on 29 March 2000 (29.03.00);
original claims 1-12 replaced by new claims 1-16 (3 pages)]

1. A process for producing an iron-dextran compound, in which the molecular weight of a dextran is 5 reduced by hydrolysis, and functional aldehyde terminal groups thereof converted into alcohol groups by hydrogenation; said dextran as an aqueous solution is combined with at least one water-soluble ferric salt; base is added to the resulting solution to form ferric 10 hydroxide, and the resulting mixture is heated to transform the ferric hydroxide into ferric oxyhydroxide as an association compound with the dextran, characterized in that the hydrogenation is only partial, leaving, however, at the most 15% by 15 weight reducing sugar, calculated on the total amount of carbon hydrates, and said dextran before being combined with the ferric salt, and after being subjected to hydrogenation is subjected to an oxidation, said hydrogenation and oxidation being performed to 20 obtain dextran having substantially all aldehyde groups converted into alcohol and carboxylic groups.

2. A process according to claim 1, characterized in that the dextran before being combined with the at least one ferric salt has a weight 25 mean molecular weight less than 7,000 Da.

3. A process according to claim 1 or 2, characterized in that after the hydrolysis, but before being combined with the water-soluble ferric salt, the dextran is purified by one or more 30 membrane separations having a cut-off value suitable for holding back dextran molecules above 2,700 Da, possibly followed by further hydrolysis and one or more membrane separations having a cut-off value between 340 and 800 Da removing the smaller molecules.

4. A process according to any of claims 1-3, characterized in that the dextran molecules have a reducing sugar content not above 4% b.w. after the oxidation.

5 5. A process according to any of claims 1-4, characterized in that the hydrogenation is performed by means of sodium borohydride in aqueous solution.

10 6. A process according to any of claims 1-5, characterized in that the oxidation is performed by means of a hypochlorite, preferably sodium hypochlorite in basic aqueous solution.

15 7. A process according to any of the preceding claims, characterized in the following steps:

preparing an aqueous solution comprising the hydrogenated and oxidized dextran and at least one water-soluble ferric salt;

20 adjusting the pH of said aqueous solution to a value above 10 by addition of a base;

heating the mixture to a temperature above 100°C until it turns into a black or dark brown colloidal solution and is filterable through a 0.45 µm filter;

25 purification and stabilization of the solution using filtration, heating and membrane separations and addition of one or more stabilizers, and

optionally drying the solution to obtain the desired iron-dextran compound as a stable powder.

30 8. A process according to claim 7, characterized in that the stabilisation comprises addition of at least one salt of an organic hydroxy acid, preferably selected from citrates and gluconates.

35 9. A process for producing a dextran preparation, in which process the molecular weight of a dextran is reduced by hydrolysis, and functional aldehyde terminal

groups thereof converted into alcohol groups by hydrogenation; characterized in that the hydrogenation is only partial, leaving, however, at the most 15% by weight reducing sugar, calculated on the 5 total amount of carbon hydrates, and said dextran is subsequently subjected to oxidation, said hydrogenation and oxidation being performed to obtain dextran having substantially all aldehyde groups converted into alcohol and carboxylic groups.

10 10. Iron-dextran compound produced according to claims 1-8, characterized in that its apparent peak molecular weight (Mp) is 50.000-150.000 Da, preferable 70.000-130.000, more preferable 80.000-120.000 Da and its iron content is 15-45 % b.w..

15 11. Dextran preparation obtainable by a process according to claim 9.

12. Dextran preparation according to claim 11, obtained by a process according to claim 9.

13. A pharmaceutical composition for prophylaxis 20 or treatment of iron-deficiency by parenteral administration comprising a compound according to claim 10.

14. A pharmaceutical composition according to claim 13, characterized in that it comprises a salt of an organic hydroxy acid, preferably 25 selected from citrates and gluconates as stabilizer.

15. Use of an iron-dextran compound according to claim 10, for preparation of a parenterally administrable therapeutical composition for prophylaxis or treatment of iron-deficiency by parenteral administration. 30

16. Use of an dextran preparation obtainable by a process according to claim 9, for the production of an iron-dextran compound.

STATEMENT UNDER ARTICLE 19

The enclosed new claims are amended as follows:

claims 1-8 are maintained unchanged;

a new claim 9 claiming a process for producing a dextran product which is an intermediate product in the production of the claimed iron-dextran;

two new claims 11 and 12 claiming the dextran product;

a new claim 16 claiming the use of the dextran product for production of iron-dextran compounds;

the original claims 9 and 10-12 have been renumbered to 10 and 13-15 respectively.

The new claims 9, 11 and 12 are supported in the description as filed on page 8 line 25 to page 10 line 30 and in Example I (i) where the preparation of the dextran product is described.

The new claim 16 is supported in the description as filed page 10 line 31 to page 11 line 16 and in Example I (ii), Example II (ii) and Example 3 where uses of the dextran product for production of iron-dextran compounds are described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00425

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/715 A61K31/295 A61K47/48 C08B37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 370 476 A (USHER THOMAS C ET AL) 25 January 1983 (1983-01-25) column 2, line 11 -column 3, line 53 ---	1-12
Y	WO 97 17377 A (ABBOTT LAB) 15 May 1997 (1997-05-15) page 3, line 7 -page 4, line 25 ---	1-12
Y	EP 0 150 085 A (POLYDEX PHARMA) 31 July 1985 (1985-07-31) page 4 ---	1-12
Y	EP 0 634 174 A (TAKEDA CHEMICAL INDUSTRIES LTD) 18 January 1995 (1995-01-18) claims ---	1-12 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

6 October 1999

14/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/DK 99/00425

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 234 209 A (FLORAMO N.A.) 8 February 1966 (1966-02-08) claims -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 99/00425

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 4370476	A 25-01-1983	NONE			
WO 9717377	A 15-05-1997	CA 2236003 A	15-05-1997	EP 0859795 A	26-08-1998
EP 0150085	A 31-07-1985	US 4788281 A	29-11-1988	CA 1265790 A	13-02-1990
		JP 61233001 A	17-10-1986		
EP 0634174	A 18-01-1995	CA 2127900 A	14-01-1995	JP 7076524 A	20-03-1995
US 3234209	A 08-02-1966	NONE			

CLAIMS

5 1. Optical method of measuring precipitation,
said precipitation being collected by means for
collecting precipitation and guided in the shape of drops
to a fluid output via a measuring zone,
10 each drop in the measuring zone passing at least one
optical path between optical transmitting means and
optical receiving means,
15 each optical receiving means outputting an electrical
signal to a calculation unit in dependence of the
intensity of the light signal received at the optical
receiving means,
20 said calculation unit being established to registration
of the number of passing drops in said at least one
optical path in dependence of said electrical signal,
25 characterised in that the optical transmitting means (5)
is established to modulation of the light emitted from
the optical transmitting means.
30 2. Method according to claim 1, characterised in that the
optical signals emitted from the optical transmitting
means (5) comprises of pulses (20, 21).
3. Electronically optical rain gauge comprising means for
collecting rainwater

and means for converting the said collected rainwater from said means into drops of certain predefined dimensions in at least one well-defined drop path,

5 at least one measuring zone arranged relatively to said
converting means comprising optical transmitting means
and optical receiving means defining at least one mutual
optical path from the optical transmitting means to the
optical receiving means,

10

said optical transmitting means being arranged for emitting light in dependence of a controlling electrical signal.

15 said optical receiving means being arranged to establish
an electrical signal in dependence of the light received
by said optical receiving means

20 said measuring zone being arranged in such a way that at least one of the said at least one drop paths passes at least one of the mutual optical paths.

25 said optical receiving means being electrical connected to calculation means, said calculation means being adapted to register the number of said passing drops in the said optical path in dependence of the said optical signal.

characterised in that the optical transmitting means are adapted to emit modulated light in dependence of a controlling electrical signal.

4. Electronically optical rain gauge according to claim 3, characterised in that the optical transmitting means

(5) are established to emit optical pulse signals (20, 21).

5. Electronically optical rain gauge according to claim 3
5 or 4, characterised in that the optical transmitting
means (5) are established to emit optical pulse signals
having a constant period and a constant duty cycle, said
duty cycle being the duration of the time the optical
transmitting means emits light over the total period
10 time.

15. Electronically optical rain gauge according to claims
3 - 5, characterised in that the duty cycle of the pulse
train is approximately 1%, and that the period time of
15 the pulse train is approximately 32 ms.

20. Electronically optical rain gauge according to claims
3 - 6, characterised in that the rain gauge comprises a
signal interface connected with the calculation means (7)
for transferring data to an external unit, said data
comprising representations of the measured drop flow or
processed data thereof.

25. Electronically optical rain gauge according to claims
3 - 7, characterised in that the calculation means
converts the number of registered drops to a measure
representation, which successively is displayed on a
display unit.

30. Electronically optical rain gauge according to claim 3
- 8, characterised in that the distance between the
optical transmitting means (5) and the optical receiving
means (9) are approximately 10 mm when the drop size is
approximately 5/100 ml.

10. Electronically optical rain gauge according to claim 3 - 9, characterised in that the means for collecting rainwater (1) and the coupled means for converting the collected rainwater to drops (2) is coupled to, or 5 comprises, a filter for reduction of the drop flow fed into the drop path or the drop paths.

11. Electronically optical rain gauge according to claim 3 - 10, characterised in that the filter for reduction of 10 the drop flow comprises a sponge (3).

12. Electronically flowmeter comprising
means for converting a transparent fluid into drops of a 15 predefined dimension, said drops being transmitted from the means in a well-defined drop path to a measuring zone
said measuring zone comprising optical transmitting means and optical receiving means defining at least one mutual 20 optical path from the optical transmitting means to the optical receiving means,

25 said optical transmitting means being arranged for emitting light in dependence of a controlling electrical signal,

30 said optical receiving means being arranged to establish an electrical signal in dependence of the light received by said optical receiving means

35 said measuring zone being arranged in such a way that at least one of the said at least one drop path passes at least one of the mutual optical paths,

D E P A T E M E N T
O F P A T E N T S
U. S. P. T. O.

said optical receiving means being electrical connected to calculation means, said calculation means being adapted to register the number of said passing drops in the said optical path in dependence of the said optical
5 signal,

characterised in that the optical transmitting means (5) are adapted to emit modulated light in dependence of a controlling electrical signal.

10

13. Electronically optical flowmeter according to claim 12, characterised in that the optical transmitting means (5) are established to emit optical pulse signals (20, 21).

15

24 April 2002



A J PARK
DX SP20064
Wellington

Patent Application No: 508225
In the Name of: PHARMACOSMOS HOLDING A/S
Your ref: P435278 NT/kfg

Examination Report

Thank you for your application that became examinable under the National Phase (under section 26(G)) on 20 June 2001.

Examination has been performed on the specification as filed and amended pages 5, 5a, and claim pages 1, 2, 3 received with the IPER.

1. Formal claim pages showing correct page numbering are awaited.
2. **Section 10(3)(b):**

Claim 13 and 14 mention a pharmaceutical composition for prophylaxis or treatment of iron-deficiency anemia by parenteral administration. The description mentions that the invention includes a pharmaceutical composition that comprises the dextran compound produced according to the described process yet the method for the production of the pharmaceutical composition is insufficiently described. In this respect the invention and the method of performing the invention is not particularly described.
3. **Section 10(4):**
 - 3.1. Claim 1 and 9: The use of the word "however" appears to be unnecessary for these claims.
 - 3.2. Claim 10: It appears that the full stops in the peak molecular weights should be replaced by commas.
 - 3.3. Claims 10: The range for the apparent molecular weight (Mp) of 50,000 to 150,000 Da is considered to be overly broad. The Applicant exemplifies no broader range than 80,000 to 130,000.
 - 3.4. Claims 11,16: The use of the word "obtainable" renders the scope of the claim unclear as it implies the dextran preparation may be obtained by some other unrelated method not contemplated by the applicant. To remain fairly based on the disclosure, the word *obtainable* should be amended to *obtained*.

The Intellectual Property Office is a business unit of the Ministry of Economic Development

4. Section 13:

As a result of investigation under Section 13, it appears the invention as claimed has been prior published in:

Citation	Date Available	Relevant part of Citation	Claim(s) cited against
NZ 150358	12 Mar 1970	See the whole document	Claims 1 and 9
NZ 150980	Before Filing date	See the whole document	Claims 1 and 9

The time for completion of all matters expires on **22 July 2003**. An extension of time of up to three months may be requested under Section 19(2).

If you have any questions please contact me.

Yours sincerely



Dayle Callaghan
for Commissioner of Patents, Trade Marks and Designs
Direct Dial (04) 560 1650